Zealand Pharma, Generate Biomedicines Partner on AI-Designed Protein Therapeutics
Collaboration targets metabolic diseases through machine learning–engineered candidates, expanding both parties' pipeline reach.
Zealand Pharma and Generate Biomedicines announced a collaboration and license agreement to develop protein therapeutics designed using artificial intelligence for treatment of metabolic diseases.
Under the terms of the agreement, Generate Biomedicines will engineer novel protein candidates leveraging its AI platform, with Zealand Pharma holding exclusive rights to develop and commercialize the resulting therapeutic candidates. The partnership marries Generate's computational protein design capabilities with Zealand's expertise in metabolic disease treatment and commercial infrastructure.
The deal structure grants Zealand Pharma global rights to candidates emerging from the collaboration. Generate Biomedicines will receive upfront payments, milestone fees tied to development and regulatory achievements, and royalties on net sales. Financial terms were not disclosed.
Metabolic disease represents a significant market opportunity, with conditions including obesity, diabetes, and related disorders driving substantial unmet clinical need. By combining AI-engineered proteins with Zealand's established development and commercialization track record, the partners aim to accelerate candidate identification and reduce time-to-clinic compared to traditional discovery methods.
Zealand Pharma has built its portfolio primarily through internal development and prior licensing agreements focused on GLP-1 receptor agonists and related modalities. This partnership marks an expansion into AI-driven protein engineering, signaling the company's strategy to diversify its therapeutic pipeline beyond its core competencies. Generate Biomedicines' computational platform enables rapid design iteration and optimization of protein sequences, addressing a bottleneck in traditional protein therapeutic development.
The collaboration underscores growing momentum in AI-assisted drug discovery, particularly within metabolic disease, where multiple pharmaceutical companies have accelerated investment in machine learning–enabled platforms. For Zealand Pharma, the agreement provides access to differentiated candidates without building internal computational infrastructure; for Generate Biomedicines, the deal validates its platform economics and extends its market reach through a partner with established regulatory relationships and commercial channels in metabolic disease.